¼¼°èÀÇ ¼ö¸·¿° Áø´Ü °Ë»ç ½ÃÀå
Meningitis Diagnostic Testing
»óǰÄÚµå : 1655523
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 174 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,301,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,905,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ¼ö¸·¿° Áø´Ü °Ë»ç ½ÃÀåÀº 2030³â±îÁö 1¾ï 5,900¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 1¾ï 2,910¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ¼ö¸·¿° Áø´Ü °Ë»ç ½ÃÀåÀº 2024-2030³â¿¡ CAGR 3.5%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 1¾ï 5,900¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ Ãø¹æÀ¯µ¿ ¾î¼¼ÀÌ´Â CAGR 4.2%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á±îÁö 2,830¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. PCR ¾î¼¼ÀÌ ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 3.7%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 3,420¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 5.2%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¼ö¸·¿° Áø´Ü °Ë»ç ½ÃÀåÀº 2024³â¿¡´Â 3,420¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 3,230¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 5.2%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 2.4%¿Í 2.7%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.7%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ¼ö¸·¿° Áø´Ü °Ë»ç ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

Çö´ë ÀÇ·á¿¡¼­ ¼ö¸·¿° Áø´Ü °Ë»ç°¡ Áß¿äÇÑ ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

¼ö¸·¿° Áø´Ü °Ë»ç´Â ¼¼±Õ¼º, ¹ÙÀÌ·¯½º¼º, Áø±Õ¼º ¼ö¸·¿°ÀÇ »ç·Ê¸¦ ½Äº°Çϰí Àû½Ã¿¡ Ä¡·áÇÒ ¼ö ÀÖÀ¸¸ç ³ú ¼Õ»ó ¹× »ç¸ÁÀ» Æ÷ÇÔÇÑ ½É°¢ÇÑ ÇÕº´ÁõÀÇ À§ÇèÀ» ÁÙÀÌ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù. ¼ö¸·¿°Àº ³ú¿Í ô¼ö¸·ÀÇ ¿°ÁõÀ¸·Î »ý¸íÀ» À§ÇùÇÒ ¼ö ÀÖÀ¸¹Ç·Î ºü¸¥ Áø´ÜÀÌ ÇÊ¿äÇÕ´Ï´Ù. ƯÈ÷ º´¿øÀ̳ª °øÁߺ¸°Ç½Ã¼³°ú °°ÀÌ ¹ßº´À» ¿¹¹æÇϱâ À§ÇØ ½Å¼ÓÇÑ ´ëÀÀÀÌ ÇʼöÀûÀΠȯ°æ¿¡¼­´Â Á¶±â¿¡ Á¤È®ÇÑ Áø´ÜÀÌ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ¼ö¸·¿°¿¡ ´ëÇÑ Àνİú Á¶±â °³ÀÔÀÇ Çʿ伺ÀÌ ³ô¾ÆÁü¿¡ µû¶ó Àü ¼¼°è ÀÇ·á ½Ã½ºÅÛ¿¡¼­ ½Å·ÚÇÒ ¼ö ÀÖ´Â Áø´Ü °Ë»ç ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

¼ö¸·¿° Áø´Ü °Ë»ç´Â ¾î¶² ±â¼ú ¹ßÀüÀÌ ¼ö¸·¿° Áø´Ü °Ë»ç¸¦ º¯È­½Ãų °ÍÀΰ¡?

ºÐÀÚÁø´Ü ¹× ÇöÀå °Ë»ç ±â¼úÀÇ ¹ßÀüÀ¸·Î ¼ö¸·¿° Áø´Ü °Ë»çÀÇ Á¤È®¼º, ½Å¼Ó¼º, Á¢±Ù¼ºÀÌ Çâ»óµÇ¾î ¼ö¸·¿° Áø´Ü °Ë»ç¿¡ º¯È­¸¦ °¡Á®¿Ô½À´Ï´Ù. ÁßÇÕÈ¿¼Ò¿¬¼â¹ÝÀÀ(PCR) °Ë»ç¿Í ½Ç½Ã°£ PCRÀº ³úô¼ö¾×³» ¼¼±Õ ¹× ¹ÙÀÌ·¯½º º´¿øÃ¼ÀÇ °ËÃ⠹ਵµ¸¦ Çâ»ó½ÃÄÑ ±âÁ¸ ¹è¾ç¹ýº¸´Ù ´õ ºü¸£°í Á¤È®ÇÑ °á°ú¸¦ ¾òÀ» ¼ö ÀÖ°Ô Çß½À´Ï´Ù. ¶ÇÇÑ ½Å¼Ó Ç׿ø °ËÃâ¹ý°ú Ãø¹æÀ¯µ¿ ¾î¼¼ÀÌÀÇ ¹ßÀüÀ¸·Î ƯÁ¤ À¯ÇüÀÇ ¼ö¸·¿°À» Áø·á ÇöÀå¿¡¼­ Áø´ÜÇÒ ¼ö ÀÖ°Ô µÇ¾ú°í, ½ÇÇè½Ç ºÐ¼®¿¡ ¼Ò¿äµÇ´Â ½Ã°£À» ´ÜÃàÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ÀÇ·áÁøÀÌ º¸´Ù ½Å¼ÓÇϰí Á¤È®ÇÑ Áø´ÜÀ» ÅëÇØ ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÏ°í ¹ßº´À» ¾ïÁ¦ÇÒ ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù.

¼ö¸·¿° Áø´Ü °Ë»ç°¡ °¡Àå ÇÊ¿äÇÑ Áý´Ü°ú ÀÇ·á ºÎ¹®Àº?

¿µ¾Æ, À¯¾Æ, À¯¾Æ, ³ëÀÎ, ¸é¿ª·ÂÀÌ ¾àÇÑ È¯ÀÚ µî °íÀ§Ç豺Àº ¼ö¸·¿°¿¡ ƯÈ÷ Ãë¾àÇϹǷΠ¼Ò¾Æ°ú ¹× ³ëÀÎ º¸°Ç ½Ã¼³¿¡¼­ ¿ì¼±ÀûÀ¸·Î °Ë»çÇØ¾ß ÇÕ´Ï´Ù. º´¿ø, ÀÀ±ÞÀÇ·á¼¾ÅÍ, °øÁߺ¸°Ç¿¬±¸¼Ò´Â ¼ö¸·¿° °Ë»ç ¼Ö·ç¼ÇÀ» ¼±µµÀûÀ¸·Î äÅÃÇÏ¿© Áø´ÜÀ» È®Á¤Çϰí Áö¿ª»çȸ³» °¨¿° È®»êÀ» ¹æÁöÇÏ´Â µ¥ »ç¿ëÇϰí ÀÖ½À´Ï´Ù. ¼ö¸·¿°ÀÌ ´õ ÈçÇÏ°Ô ¹ß»ýÇÏ´Â ½ÅÈï ±¹°¡¿¡¼­´Â ¼ö¸·¿°ÀÇ ºÎ´ãÀ» ÇØ°áÇϱâ À§ÇØ Áø´Ü °Ë»ç¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» ³ôÀÌ´Â µ¥ ÁßÁ¡À» µÎ°í °øÁߺ¸°Ç ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±¤¹üÀ§ÇÑ ¼ö¿ä´Â ´Ù¾çÇÑ ÀÇ·á ȯ°æ°ú Àα¸ Áý´Ü¿¡¼­ ¼ö¸·¿° Áø´Ü ¼Ö·ç¼ÇÀÇ Áß¿äÇÑ Çʿ伺À» °­Á¶Çϰí ÀÖ½À´Ï´Ù.

¼ö¸·¿° Áø´Ü °Ë»ç ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÃËÁø

¼ö¸·¿° Áø´Ü Å×½ºÆ® ½ÃÀåÀÇ ¼ºÀåÀº ¼ö¸·¿° Áõ»ó¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ½Å¼Ó Áø´Ü ±â¼úÀÇ ¹ßÀü, °øÁß º¸°Ç ±¸»óÀÇ ½ÃÇà µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. Á¶±â Áø´ÜÀÇ Á߿伺¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ƯÈ÷ °íÀ§Çè Áö¿ª¿¡¼­ Á¤È®ÇÑ °Ë»ç ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, PCR ¹× Ç׿ø ±â¹Ý ½Å¼Ó °Ë»ç¿Í °°Àº ±â¼ú Çõ½ÅÀº Áø´Ü ¼Óµµ¿Í ¹Î°¨µµ¸¦ Çâ»ó½ÃÄÑ ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õÀÇ ¿ä±¸¸¦ ÃæÁ·½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¼ö¸·¿° ¿¹¹æ ¹× ÅëÁ¦¿¡ ÁßÁ¡À» µÐ °øÁߺ¸°Ç ÇÁ·Î±×·¥Àº ƯÈ÷ ¹ßº´ÀÌ ºó¹øÇÑ Áö¿ª¿¡¼­ Áø´Ü °Ë»ç¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» ³ô¿© ½ÃÀå È®´ëÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.

ºÎ¹®

ÃÖÁ¾»ç¿ëÀÚ »ê¾÷(º´¿ø, Áø´Ü¼¾ÅÍ, ±âŸ ÃÖÁ¾»ç¿ëÀÚ »ê¾÷) ; & Á¦Ç°(Ãø¹æÀ¯µ¿ ¾î¼¼ÀÌ, PCR ºÐ¼®, ELISA Å×½ºÆ®, ¹è¾ç Å×½ºÆ®, ±âŸ Á¦Ç°)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÁÖ¸ñ 43»ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Meningitis Diagnostic Testing Market to Reach US$159.0 Million by 2030

The global market for Meningitis Diagnostic Testing estimated at US$129.1 Million in the year 2024, is expected to reach US$159.0 Million by 2030, growing at a CAGR of 3.5% over the analysis period 2024-2030. Lateral Flow Assay, one of the segments analyzed in the report, is expected to record a 4.2% CAGR and reach US$28.3 Million by the end of the analysis period. Growth in the PCR Assay segment is estimated at 3.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$34.2 Million While China is Forecast to Grow at 5.2% CAGR

The Meningitis Diagnostic Testing market in the U.S. is estimated at US$34.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$32.3 Million by the year 2030 trailing a CAGR of 5.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.4% and 2.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR.

Global Meningitis Diagnostic Testing Market - Key Trends & Drivers Summarized

Why Is Meningitis Diagnostic Testing Critical in Modern Healthcare?

Meningitis diagnostic testing is essential for identifying cases of bacterial, viral, and fungal meningitis, enabling timely treatment and reducing the risk of severe complications, including brain damage and death. Meningitis, an inflammation of the brain and spinal cord membranes, requires rapid diagnosis due to its potentially life-threatening nature. The importance of early and accurate diagnosis is particularly high in settings like hospitals and public health facilities, where swift action is crucial in preventing outbreaks. As awareness around meningitis and the need for early intervention grows, the demand for reliable diagnostic testing solutions has increased across healthcare systems worldwide.

What Technological Advancements Are Transforming Meningitis Diagnostic Testing?

Technological advancements in molecular diagnostics and point-of-care testing have transformed meningitis diagnostic testing, improving accuracy, speed, and accessibility. Polymerase chain reaction (PCR) testing and real-time PCR have enhanced sensitivity in detecting bacterial and viral pathogens in cerebrospinal fluid, allowing for faster and more precise results than traditional culture methods. Additionally, advancements in rapid antigen detection and lateral flow assays have made it possible to diagnose certain types of meningitis at the point of care, reducing the time required for laboratory analysis. These innovations are helping healthcare providers make quicker and more accurate diagnoses, improving patient outcomes and outbreak containment.

Which Populations and Healthcare Sectors Are Most in Need of Meningitis Diagnostic Testing?

High-risk populations, including infants, young children, elderly individuals, and immunocompromised patients, are particularly vulnerable to meningitis, making testing a priority in pediatric and geriatric healthcare settings. Hospitals, urgent care centers, and public health laboratories are leading adopters of meningitis testing solutions, using these tests to confirm diagnoses and prevent spread within communities. In developing countries, where meningitis outbreaks are more common, public health initiatives have focused on increasing access to diagnostic testing to address the burden of the disease. This widespread demand underscores the critical need for meningitis diagnostic solutions across various healthcare settings and population groups.

The Growth in the Meningitis Diagnostic Testing Market Is Driven by Several Factors

The growth in the meningitis diagnostic testing market is driven by several factors, including increasing awareness of meningitis symptoms, advancements in rapid diagnostic technology, and the implementation of public health initiatives. Rising awareness around the importance of early diagnosis has spurred demand for accurate testing solutions, especially in high-risk regions. Technological innovations, such as PCR and antigen-based rapid testing, have improved diagnostic speed and sensitivity, meeting the needs of healthcare providers. Additionally, public health programs focused on meningitis prevention and control have increased access to diagnostic testing, particularly in outbreak-prone areas, driving market expansion.

SCOPE OF STUDY:

The report analyzes the Meningitis Diagnostic Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

End-Use Industry (Hospitals, Diagnostic Centers, Other End-Use Industries); Product (Lateral Flow Assay, PCR Assay, ELISA Tests, Culture Test, Other Products)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â